cancer of the lymph nodes Lymphoma
Conditions
Interventions
- At the first visit when patients are randomized, blood will be drawn and the
first vaccination with Prevnar 13 and Act-Hib will be given.
- 3 weeks later, blood will be drawn.
- 2 months later, the
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients with non-Hodgkin*s lymphoma, treated with rituximab (with a range of 6-12 cycles) and who are in remission. 2. Completion of rituximab therapy in the last five months before start of the study. 3. Age * 18 years. 4. Signing of informed consent.
Exclusion criteria
Exclusion criteria: 1. Completion of rituximab therapy >5-6 months before start of the study. 2. Fever at time of vaccination. 3. Previous/known allergic reaction to any of the components of the vaccines given. 4. Vaccination with Hib or pneumococcal vaccine in the last fifteen months before start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody titres against S. Pneumonia and H. influenzae type b (in *g/mL) vaccine before and after vaccinations. Titres will be interpreted and classified in responder or non-responder. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Immunoglobulin levels and subclass. - Lymphocyte subsets (number of B cells and memory-B cells, CD3, CD4, CD8 and NK cells). - Production of IFN-gamma by CD4+ cells. This will be measured in order to investigate if cellular mediated immune responses are intact after rituximab treatment. - Cytokines and genetic factors (for example BAFF, CXCL13, APRIL) influencing B cell development and survival will be measured in order to determine if there is a correlation between specific cytokines/genetic factors and the observed B-cell depletion/reconstitution. - Serum rituximab levels. | — |
Countries
Netherlands
Outcome results
None listed